por Lauren Dubinsky
, Senior Reporter | May 15, 2020
A research team at Tel Aviv Sourasky Medical Center in Israel recently discovered that a new PET/CT radiotracer can detect more prostate cancer lesions than 68Ga-PSMA-11 and has a significantly longer half-life.
“18F-PSMA-1007 is a promising novel tracer for imaging prostate cancer with several advantages over 68Ga-PSMA,” Dr. Einat Even-Sapir, director of the Institute for Nuclear Medicine at the medical center, told HCB News.
She is hopeful that the new radiotracer could represent another option for physicians ordering PET/CT scans, and stressed that it is not intended to replace 68Ga-PSMA-11, which is the current gold standard.
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
“We feel that there is room for both tracers in the evaluation of prostate cancer and that clinicians can choose whichever is more readily available to them or based on their local experience and preference,” Even-Sapir explained.
For the study, 16 patients with newly diagnosed intermediate- or high-risk prostate cancer underwent 18F-PSMA-1007 PET/CT scans and then 68Ga-PSMA-11 PET/CT scans 15 days later. The data from the scans was compared to histopathologic findings obtained from their radical prostatectomies.
Both radiotracers detected PSMA-avid lesions in the prostates of all 16 patients with almost the same tumor location, while 18F-PSMA-1007 detected four additional lesions — three of which were confirmed areas of prostate cancer.
Another advantage of 18F-PSMA-1007 is its 109-minute half-life compared to 68Ga-PSMA-11’s 68-minute half-life. Even-Sapir explained that 18F-PSMA-1007’s half-life is longer since it is derived from the physical properties of 18F.
Despite those advantages, there is still a prominent place for 68Ga-PSMA-11 in prostate cancer imaging. Just last year, research was presented at the Society of Nuclear Medicine and Molecular Imaging annual meeting that found 68Ga-PSMA-11 is better at detecting prostate cancer lesions than 18F-fluciclovine.
“68Ga-PSMA is an established radiopharmaceutical, one which we are comfortable working with and has so far performed very well for us,” said Even-Sapir. “The present study shows that 18F-PSMA-1007 may be used interchangeably with 68Ga-PSMA.”
She currently uses both radiotracers in her own clinical practice.